Phage therapy for adults with cystic fibrosis and achromobacter infection
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This trial tests a cocktail of viruses (bacteriophages) that target achromobacter bacteria in the lungs of adults with cystic fibrosis. It aims to see if the phages are safe and can reduce the infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and weigh at least 88 pounds (40 kg).
- You have cystic fibrosis (CF) and a stable respiratory condition for the past month.
- You have had achromobacter bacteria in your lungs, throat, or nose at least twice in the last 2 years.
- A recent sample (within 2 months) of your achromobacter must be killed by the study phage cocktail.
- Your lung function (FEV1) must be at least 40% of normal for your age and size.
- You must be willing to travel to the University of Pittsburgh or UC San Diego for treatment and visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using phages (viruses that kill bacteria) for people with cystic fibrosis who have a chronic pseudomonas lung infection. It aims to see if adding phages to your usual care can help control the infection.
This trial tests an inhaled mRNA therapy (BMD003) for adults with cystic fibrosis. It aims to see if the treatment is safe and can help improve lung function.
This trial tests whether adding a special virus (bacteriophage) that kills antibiotic-resistant bacteria to standard IV antibiotics is safe for people with cystic fibrosis. It is for adults whose lung infections are hard to treat because the bacteria have stopped responding to usual antibiotics.
This trial tests whether a special virus therapy (phage) can help clear stubborn NTM lung infections in people with cystic fibrosis who have been on antibiotics for over a year without success. Participants will continue their antibiotics while receiving the phages.
This trial tests whether a cocktail of bacteriophages (viruses that kill bacteria) can treat ventilator-associated pneumonia caused by hard-to-treat bacteria like Klebsiella, Acinetobacter, or Pseudomonas. It may help patients who have not responded to standard antibiotics.
This trial tests whether bacteriophages—viruses that kill bacteria—can help treat a chronic lung infection caused by a drug-resistant bacterium called Mycobacterium abscessus.
Hear when a new Cystic Fibrosis (CF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.